Multifocal endometriotic lesions associated with cancer are clonal and carry a high mutation burden

Journal of Pathology

Volumn 236, Issue 2, 2015, Pages 201-209

  Anglesio, Michael S ^a   Bashashati, Ali ^b   Wang, Yi Kan ^b   Senz, Janine ^a   Ha, Gavin ^b   Yang, Winnie ^b   Aniba, Mohamed R ^b   Prentice, Leah M ^b   Farahani, Hossein ^b   Li Chang, Hector ^a   Karnezis, Anthony N ^a   Marra, Marco A ^b   Yong, Paul J ^a   Hirst, Martin ^b,c   Gilks, Blake ^a,d   Shah, Sohrab P ^a,b   Huntsman, David G ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d VANCOUVER GENERAL HOSPITAL   (Canada)

Author keywords

cancer precursor; clear cell carcinoma; endometriosis; ovarian cancer; sequencing

Indexed keywords

ARTICLE; CANCER GROWTH; CLEAR CELL CARCINOMA; CLINICAL ARTICLE; DISEASE ASSOCIATION; ENDOMETRIOSIS; FEMALE; GENE SEQUENCE; GENETIC RISK; GENOME; HUMAN; HUMAN TISSUE; MALIGNANT TRANSFORMATION; MOLECULAR CLONING; MULTIGENE FAMILY; OVARY CARCINOMA; PRIORITY JOURNAL; RISK FACTOR; SOMATIC MUTATION; ADENOCARCINOMA; DNA SEQUENCE; GENETIC ASSOCIATION; GENETICS; MUTATION; OVARY TUMOR; PRECANCER;

ARID1A PROTEIN, HUMAN; DNA; NUCLEAR PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ADENOCARCINOMA, CLEAR CELL; DNA, NEOPLASM; ENDOMETRIOSIS; FEMALE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MUTATION; NUCLEAR PROTEINS; OVARIAN NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PRECANCEROUS CONDITIONS; SEQUENCE ANALYSIS, DNA; TRANSCRIPTION FACTORS;

EID: 84929271622     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4516     Document Type: Article

References (44)

1. Rogers PA, D'Hooghe TM, Fazleabas A, et al., Defining future directions for endometriosis research: workshop report from the 2011 World Congress of Endometriosis in Montpellier, France. Reprod Sci 2013; 20: 483-499.
2. Eskenazi B, Warner ML,. Epidemiology of endometriosis. Obstet Gynecol Clin N Am 1997; 24: 235-258.
3. Burney RO, Giudice LC,. Pathogenesis and pathophysiology of endometriosis. Fertil Steril 2012; 98: 511-519.
4. Anglesio MS, Carey MS, Kobel M, et al., Clear cell carcinoma of the ovary: a report from the first Ovarian Clear Cell Symposium, June 24th, 2010. Gynecol Oncol 2011; 121: 407-415.
5. Merritt MA, Green AC, Nagle CM, et al., Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer. Int J Cancer 2008; 122: 170-176.
6. Pearce CL, Templeman C, Rossing MA, et al., Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol 2012; 13: 385-394.
7. Heidemann LN, Hartwell D, Heidemann CH, et al., The relation between endometriosis and ovarian cancer-a review. Acta Obstet Gynecol Scand 2014; 93: 20-31.
8. LaGrenade A, Silverberg SG,. Ovarian tumors associated with atypical endometriosis. Hum Pathol 1988; 19: 1080-1084.
9. Vercellini P, Parazzini F, Bolis G, et al., Endometriosis and ovarian cancer. Am J Obstet Gynecol 1993; 169: 181-182.
10. Jiang X, Morland SJ, Hitchcock A, et al., Allelotyping of endometriosis with adjacent ovarian carcinoma reveals evidence of a common lineage. Cancer Res 1998; 58: 1707-1712.
11. Prowse AH, Manek S, Varma R, et al., Molecular genetic evidence that endometriosis is a precursor of ovarian cancer. Int J Cancer 2006; 119: 556-562.
12. Campbell IG, Thomas EJ,. Endometriosis: candidate genes. Hum Reprod Update 2001; 7: 15-20.
13. Wiegand KC, Shah SP, Al-Agha OM, et al., ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 2010; 363: 1532-1543.
14. Jones S, Wang TL, Shih Ie M, et al., Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science (New York, NY) 2010; 330: 228-231.
15. Yamamoto S, Tsuda H, Miyai K, et al., Accumulative copy number increase of MET drives tumor development and histological progression in a subset of ovarian clear-cell adenocarcinomas. Mod Pathol 2012; 25: 122-130.
16. Yamamoto S, Tsuda H, Miyai K, et al., Gene amplification and protein overexpression of MET are common events in ovarian clear-cell adenocarcinoma: their roles in tumor progression and prognostication of the patient. Mod Pathol 2011; 24: 1146-1155.
17. McKernan KJ, Peckham HE, Costa GL, et al., Sequence and structural variation in a human genome uncovered by short-read, massively parallel ligation sequencing using two-base encoding. Genome Res 2009; 19: 1527-1541.
18. Eirew P, Steif A, Khattra J, et al., Dynamics of genomic clones in breast cancer patient xenografts at single cell resolution. Nature 2015; 518: 422-426.
19. Sung CO, Choi CH, Ko YH, et al., Integrative analysis of copy number alteration and gene expression profiling in ovarian clear cell adenocarcinoma. Cancer Genet 2013; 206: 145-153.
20. Kuo KT, Mao TL, Chen X, et al., DNA copy numbers profiles in affinity-purified ovarian clear cell carcinoma. Clin Cancer Res 2010; 16: 1997-2008.
21. Tan DS, Lambros MB, Rayter S, et al., PPM1D is a potential therapeutic target in ovarian clear cell carcinomas. Clin Cancer Res 2009; 15: 2269-2280.
22. Tan DS, Iravani M, McCluggage WG, et al., Genomic analysis reveals the molecular heterogeneity of ovarian clear cell carcinomas. Clin Cancer Res 2011; 17: 1521-1534.
23. Anglesio MS, George J, Kulbe H, et al., IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer. Clin Cancer Res 2011; 17: 2538-2548.
24. Slamon DJ, Clark GM, Wong SG, et al., Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (New York, NY) 1987; 235: 177-182.
25. Anglesio MS, Kommoss S, Tolcher MC, et al., Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas. J Pathol 2013; 229: 111-120.
26. McAlpine JN, Wiegand KC, Vang R, et al., HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy. BMC Cancer 2009; 9: 433.
27. McConechy MK, Ding J, Senz J, et al., Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles. Mod Pathol 2014; 27: 128-134.
28. Kuo KT, Mao TL, Jones S, et al., Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol 2009; 174: 1597-1601.
29. Campbell IG, Russell SE, Choong DY, et al., Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 2004; 64: 7678-7681.
30. Belandia B, Orford RL, Hurst HC, et al., Targeting of SWI/SNF chromatin remodelling complexes to estrogen-responsive genes. EMBO J 2002; 21: 4094-4103.
31. Zhou G, Hashimoto Y, Kwak I, et al., Role of the steroid receptor coactivator SRC-3 in cell growth. Mol Cell Biol 2003; 23: 7742-7755.
32. Griesmann H, Ripka S, Pralle M, et al., WNT5A-NFAT signaling mediates resistance to apoptosis in pancreatic cancer. Neoplasia 2013; 15: 11-22.
33. Rosenbluh J, Wang X, Hahn WC,. Genomic insights into WNT/β-catenin signaling. Trends Pharmacol Sci 2014; 35: 103-109.
34. Sato Y, Yoshizato T, Shiraishi Y, et al., Integrated molecular analysis of clear-cell renal cell carcinoma. Nat Genet 2013; 45: 860-867.
35. Li XS, Trojer P, Matsumura T, et al., Mammalian SWI/SNF-a subunit BAF250/ARID1 is an E3 ubiquitin ligase that targets histone H2B. Mol Cell Biol 2010; 30: 1673-1688.
36. Wright DE, Wang CY, Kao CF,. Histone ubiquitylation and chromatin dynamics. Front Biosci 2012; 17: 1051-1078.
37. Wiegand KC, Lee AF, Al-Agha OM, et al., Loss of BAF250a (ARID1A) is frequent in high-grade endometrial carcinomas. J Pathol 2011; 224: 328-333.
38. Vogelstein B, Kinzler KW,. Cancer genes and the pathways they control. Nat Med 2004; 10: 789-799.
39. Palacios J, Gamallo C,. Mutations in the β-catenin gene (CTNNB1) in endometrioid ovarian carcinomas. Cancer Res 1998; 58: 1344-1347.
40. Andrade VP, Ostrovnaya I, Seshan VE, et al., Clonal relatedness between lobular carcinoma in situ and synchronous malignant lesions. Breast Cancer Res 2012; 14: R103.
41. Chandler R, Damrauer J, Raab J, et al., ARID1A-PIK3CA mutations promote ovarian clear-cell tumorigenesis through pro-tumorigenic inflammatory cytokine signaling. Nat Commun 2015; 6: 6118.
42. Tomasetti C, Vogelstein B, Parmigiani G,. Half or more of the somatic mutations in cancers of self-renewing tissues originate prior to tumor initiation. Proc Natl Acad Sci USA 2013; 110: 1999-2004.
43. Skulte KA, Phan L, Clark SJ, et al., Chromatin remodeler mutations in human cancers: epigenetic implications. Epigenomics 2014; 6: 397-414.
44. Kobel M, Kalloger SE, Boyd N, et al., Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med 2008; 5: e232.